Posted by Michael Wonder on 24 Jul 2024
BioAtla granted FDA fast track designation for ozuriftamab vedotin (CAB-ROR2-ADC) for treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck
23 July 2024 - Ozuriftamab vedotin, the Company’s conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in treatment refractory patients with squamous cell carcinoma of the head and neck in its Phase 2 clinical trial.
BioAtla today announced that the US FDA has granted fast track designation to ozuriftamab vedotin, the Company’s conditionally and reversibly active ROR2 antibody drug conjugate directed for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum-based chemotherapy and anti-PD-1/L1 antibody therapy.
